, Volume 186, Issue 2, pp 226–234 | Cite as

Interactions between THC and cannabidiol in mouse models of cannabinoid activity

  • S. A. VarvelEmail author
  • J. L. Wiley
  • R. Yang
  • D. T. Bridgen
  • K. Long
  • A. H. Lichtman
  • B. R. Martin
Original Investigation



Interest persists in characterizing potential interactions between Δ9-tetrahydocannabinol (THC) and other marijuana constituents such as cannabidiol (CBD). Such interactions may have important implications for understanding the long-term health consequences of chronic marijuana use as well as for attempts to develop therapeutic uses for THC and other CB1 agonists.


We investigated whether CBD may modulate the pharmacological effects of intravenously administered THC or inhaled marijuana smoke on hypoactivity, antinociception, catalepsy, and hypothermia, the well characterized models of cannabinoid activity.


Intravenously administered CBD possessed very little activity on its own and, at a dose equal to a maximally effective dose of THC (3 mg/kg), failed to alter THC’s effects on any measure. However, higher doses of CBD (ED50=7.4 mg/kg) dose-dependently potentiated the antinociceptive effects of a low dose of THC (0.3 mg/kg). Pretreatment with 30 mg/kg CBD, but not 3 mg/kg, significantly elevated THC blood and brain levels. No interactions between THC and CBD were observed in several variations of a marijuana smoke exposure model. Either quantities of CBD were applied directly to marijuana, CBD and THC were both applied to placebo plant material, or mice were pretreated intravenously with 30 mg/kg CBD before being exposed to marijuana smoke.


As the amount of CBD found in most marijuana strains in the US is considerably less than that of THC, these results suggest that CBD concentrations relevant to what is normally found in marijuana exert very little, if any, modulatory effects on CB1-receptor-mediated pharmacological effects of marijuana smoke.


Marijuana Δ9-THC Cannabidiol Intravenous Inhalation Tetrad Antinociception 



This work was supported by DA-02396 and DA-03672.


  1. Anderson PF, Jackson DM, Chesher GB (1974) Interaction of Δ9-tetrahydrocannabinol and cannabidiol on intestinal motility in mice. J Pharm Pharmacol 26:136–137PubMedGoogle Scholar
  2. Berman JS, Symonds C, Birch R (2004) Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 112:299–306PubMedCrossRefGoogle Scholar
  3. Bliss CI (1967) Statistics in biology; statistical methods for research in the natural sciences. McGraw-HillGoogle Scholar
  4. Borgen LA, Davis WM (1974) Cannabidiol interaction with Δ9-tetrahydrocannabinol. Res Commun Chem Pathol Pharmacol 7:663–670PubMedGoogle Scholar
  5. Bornheim LM, Everhart ET, Li J, Correia MA (1993) Characterization of cannabidiol-mediated cytochrome P450 inactivation. Biochem Pharmacol 45:1323–1331PubMedCrossRefGoogle Scholar
  6. Bornheim LM, Kim K, Beatrice J, Perotti Y, Benet L (1995) Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. Drug Metab Dispos 23:825–831PubMedGoogle Scholar
  7. Brady KT, Balster RL (1980) The effects of delta 9-tetrahydrocannabinol alone and in combination with cannabidiol on fixed-interval performance in rhesus monkeys. Psychopharmacology (Berl) 72:21–26CrossRefGoogle Scholar
  8. Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ (2004) An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 10:425–433PubMedCrossRefGoogle Scholar
  9. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, Di Marzo V (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134:825–852CrossRefGoogle Scholar
  10. Colquhoun D (1971) Lectures on biostatistics: an introduction to statistics with applications in biology and medicine. ClarendonGoogle Scholar
  11. Costa B, Giagnoni G, Franke C, Trovato AE, Colleoni M (2004) Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br J Pharmacol 143:247–250PubMedCrossRefGoogle Scholar
  12. D'Amour FE, Smith DL (1941) A method for determining loss of pain sensation. J Pharm Exp Ther 72:74–79Google Scholar
  13. Davis WM, Borgen LA (1974) Effects of cannabidiol and Δ9-tetrahydrocannabinol on operant behavior. Res Commun Chem Pathol Pharmacol 9:453–462PubMedGoogle Scholar
  14. ElSohly MA, Ross SA, Mehmedic Z, Arafat R, Yi B, Banahan BF 3rd (2000) Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980–1997. J Forensic Sci 45:24–30PubMedGoogle Scholar
  15. Fernandes M, Schabarek A, Coper H, Hill R (1974) Modification of Δ9-THC actions by cannabinol and cannabidiol in the rat. Psychopharmacologia 38:329–338PubMedCrossRefGoogle Scholar
  16. Finn DP, Beckett SR, Roe CH, Madjd A, Fone KC, Kendall DA, Marsden CA, Chapman V (2004) Effects of coadministration of cannabinoids and morphine on nociceptive behaviour, brain monoamines and HPA axis activity in a rat model of persistent pain. Eur J Neurosci 19:678–686PubMedCrossRefGoogle Scholar
  17. Ham MT, De Jong Y (1975) Absence of interaction between Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) in aggression, muscle control and body temperature experiments in mice. Psychopharmacologia 41:169–174PubMedCrossRefGoogle Scholar
  18. Hampson AJ, Grimaldi M, Lolic M, Wink D, Rosenthal R, Axelrod J (2000) Neuroprotective antioxidants from marijuana. Ann N Y Acad Sci 899:274–282PubMedCrossRefGoogle Scholar
  19. Harvey DJ (1984) Chemistry, metabolism, and pharmacokinetics of the cannabinoids. In: Nahas GG (ed) Marijuana in science and medicine. Raven, New York, NY, pp 33–107Google Scholar
  20. Jaeger W, Benet LZ, Bornheim LM (1996) Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes. Xenobiotica 26:275–284PubMedCrossRefGoogle Scholar
  21. Jones G, Pertwee RG (1972) A metabolic interaction in vivo between cannabidiol and 1-tetrahydrocannabinol. Br J Pharmacol 45:375–377PubMedGoogle Scholar
  22. Karniol IG, Carlini EA (1973) Pharmacological interaction between cannabidiol and Δ9-tetrahydrocannabinol. Psychopharmacologia 33:53–70PubMedCrossRefGoogle Scholar
  23. Karniol IG, Shirakawa I, Kasinaki N, Carlini EA (1974) Cannabidiol interferes with the effects of Δ9-tetrahydrocannabinol in man. Eur J Pharmacol 28:172–177PubMedCrossRefGoogle Scholar
  24. Levy S, McCallum NK (1975) Cannabidiol and its pharmacokinetic interaction with delta1-tetrahydrocannabinol. Experientia 31:1268–1269PubMedCrossRefGoogle Scholar
  25. Lichtman AH, Poklis JL, Poklis A, Wilson DM, Martin BR (2001) The pharmacological activity of inhalation exposure to marijuana smoke in mice. Drug Alcohol Depend 63:107–116PubMedCrossRefGoogle Scholar
  26. Marsicano G, Moosmann B, Hermann H, Lutz B, Behl C (2002) Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J Neurochem 80:448–456PubMedCrossRefGoogle Scholar
  27. Mechoulam R, Parker LA, Gallily R (2002) Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 42:11S–19SPubMedGoogle Scholar
  28. Nicholson AN, Turner C, Stone BM, Robson PJ (2004) Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacol 24:305–313PubMedCrossRefGoogle Scholar
  29. Ohlsson A, Lindgren JE, Andersson S, Agurell S, Gillespie H, Hollister LE (1986) Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Biomed Environ Mass Spectrom 13:77–83PubMedCrossRefGoogle Scholar
  30. Pertwee R (2004) The pharmaology and therapeutic potential of cannabidiol. In: Di Marzo V (ed) Cannabinoids. Kluwer Academic, Dordrecht, NetherlandsGoogle Scholar
  31. Pertwee RG (1972) The ring test: a quantitative method for assessing the 'cataleptic' effect of cannabis in mice. Br J Pharmacol 46:753–763PubMedGoogle Scholar
  32. Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74:129–180PubMedCrossRefGoogle Scholar
  33. Rakhshan F, Day TA, Blakely RD, Barker EL (2000) Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. J Pharmacol Exp Ther 292:960–967PubMedGoogle Scholar
  34. Rog DJ, Nurmikko TJ, Friede T, Young CA (2005) Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 65:812–819PubMedCrossRefGoogle Scholar
  35. Russo E, Guy GW (2006) A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66(2):234–246PubMedCrossRefGoogle Scholar
  36. Russo EB, Burnett A, Hall B, Parker KK (2005) Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30:1037–1043PubMedCrossRefGoogle Scholar
  37. Sanders J, Jackson DM, Starmer GA (1979) Interactions among the cannabinoids in the antagonism of abdominal constriction response in the mouse. Psychopharmacology (Berl) 61:281–285CrossRefGoogle Scholar
  38. Sofia RD, Vassar HB, Knobloch LC (1975) Comparative analgesic activity of various naturally occurring cannabinoids in mice and rats. Psychopharmacologia 40:285–295PubMedCrossRefGoogle Scholar
  39. Varvel SA, Bridgen DT, Tao Q, Thomas BF, Martin BR, Lichtman AH (2005) Delta9-tetrahydrocannabinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. J Pharmacol Exp Ther 314:329–337PubMedCrossRefGoogle Scholar
  40. Wade DT, Robson P, House H, Makela P, Aram J (2003) A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehab 17:21–29CrossRefGoogle Scholar
  41. Wade DT, Makela P, Robson P, House H, Bateman C (2004) Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 10:434–441PubMedCrossRefGoogle Scholar
  42. Watanabe K, Arai M, Narimatsu S, Yamamoto I, Yoshimura H (1987) Self-catalyzed inactivation of cytochrome P-450 during microsomal metabolism of cannabidiol. Biochem Pharmacol 36:3371–3377PubMedCrossRefGoogle Scholar
  43. Watanabe K, Kayano Y, Matsunaga T, Yamamoto I, Yoshimura H (1996) Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids. Biol Pharm Bull 19:1109–1111PubMedGoogle Scholar
  44. Welburn PJ, Starmer GA, Chesher GB, Jackson DM (1976) Effect of cannabinoids on the abdominal constriction response in mice: within cannabinoid interactions. Psychopharmacologia 46:83–85PubMedCrossRefGoogle Scholar
  45. Zuardi AW, Shirakawa I, Fenkelfarb E, Karniol IG (1982) Action of cannabidiol on the anxiety and other effects produced by Δ9-THC in normal subjects. Psychopharmacology (Berl) 76:245–250CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • S. A. Varvel
    • 1
    Email author
  • J. L. Wiley
    • 1
  • R. Yang
    • 1
  • D. T. Bridgen
    • 1
  • K. Long
    • 1
  • A. H. Lichtman
    • 1
  • B. R. Martin
    • 1
  1. 1.Department of Pharmacology and ToxicologyVirginia Commonwealth UniversityRichmondUSA

Personalised recommendations